Skip to main content

CARACTERIZACION Y DETECCION DE ALTERACIONES EN EL PROCESAMIENTO DEL RNA CON RELEVANCIA CLINICA PARA LA MEDICINA PERSONALIZADA DEL CANCER

BIO2014-52566-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers

  • Pérez-Guijarro, Eva
  • Bellora Pereyra, Nicolás
  • Eyras Jiménez, Eduardo
  • Soengas, María S.
Nuclear 3’-end-polyadenylation is essential for the transport, stability and translation of virtually all eukaryotic mRNAs. Poly(A) tail extension can also occur in the cytoplasm, but the transcripts involved are incompletely understood, particularly in cancer. Here we identify a lineage-specific requirement of the cytoplasmic polyadenylation binding protein 4 (CPEB4) in malignant melanoma. CPEB4 is upregulated early in melanoma progression, as defined by computational and histological analyses. Melanoma cells are distinct from other tumour cell types in their dependency on CPEB4, not only to prevent mitotic aberrations, but to progress through G1/S cell cycle checkpoints. RNA immunoprecipitation, sequencing of bound transcripts and poly(A) length tests link the melanoma-specific functions of CPEB4 to signalling hubs specifically enriched in this disease. Essential in these CPEB4-controlled networks are the melanoma drivers MITF and RAB7A, a feature validated in clinical biopsies. These results provide new mechanistic links between cytoplasmic polyadenylation and lineage specification in melanoma., M.S.S. was funded by Marató TVE and Consolider RNAREG (CSD2009-00080), and SAF2014-56868-R (Spanish Ministry of Economy and Innovation). R.M. was supported by Fundación Botín, by the Banco Santander through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Innovation (BFU2011–30121 and Consolider RNAREG (CSD2009-00080). J.L.R.-P. was funded by grant FIS 2014/1737 from the Spanish Ministry of Health, P.L.O.-R. by FIS 14/1784; and N.B. and E.E. by MINECO and FEDER (BIO2014-52566-R), as well as by Consolider RNAREG (CSD2009-00080), by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013). C.R.G was funded by Ludwig Institute for Cancer Research. E.P.-G., D.A.-C. and R.M.-H. are recipients of Scientists in Training predoctoral fellowships from the Spanish Ministry of Science and Innovation. P.K and M.C. are funded by a predoctoral fellowship from Fundación La Caixa. E.R.-F. is the recipient of a postdoctoral fellowship from ‘Fundación Científica de la Asociación Española Contra el Cáncer’ and supported by FMM-2013/0075 of Fundacion Mutua Madrileña.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SARNAclust: Semi-automatic detection of RNA protein binding motifs from immunoprecipitation data

  • Dotu, Ivan
  • Scott I. Adamson
  • Coleman, Benjamin
  • Fournier, Cyril
  • Ricart Altimiras, Emma
  • Eyras Jiménez, Eduardo
  • Chuang, Jeffrey H.
RNA-protein binding is critical to gene regulation, controlling fundamental processes including splicing, translation, localization and stability, and aberrant RNA-protein interactions are known to play a role in a wide variety of diseases. However, molecular understanding of RNA-protein interactions remains limited; in particular, identification of RNA motifs that bind proteins has long been challenging, especially when such motifs depend on both sequence and structure. Moreover, although RNA binding proteins (RBPs) often contain more than one binding domain, algorithms capable of identifying more than one binding motif simultaneously have not been developed. In this paper we present a novel pipeline to determine binding peaks in crosslinking immunoprecipitation (CLIP) data, to discover multiple possible RNA sequence/structure motifs among them, and to experimentally validate such motifs. At the core is a new semi-automatic algorithm SARNAclust, the first unsupervised method to identify and deconvolve multiple sequence/structure motifs simultaneously. SARNAclust computes similarity between sequence/structure objects using a graph kernel, providing the ability to isolate the impact of specific features through the bulge graph formalism. Application of SARNAclust to synthetic data shows its capability of clustering 5 motifs at once with a V-measure value of over 0.95, while GraphClust achieves only a V-measure of 0.083 and RNAcontext cannot detect any of the motifs. When applied to existing eCLIP sets, SARNAclust finds known motifs for SLBP and HNRNPC and novel motifs for several other RBPs such as AGGF1, AKAP8L and ILF3. We demonstrate an experimental validation protocol, a targeted Bind-n-Seq-like high-throughput sequencing approach that relies on RNA inverse folding for oligo pool design, that can validate the components within the SLBP motif. Finally, we use this protocol to experimentally interrogate the SARNAclust motif predictions for protein ILF3. Our results support a newly identified partially double-stranded UUUUUGAGA motif similar to that known for the splicing factor HNRNPC., JHC was supported by NIH grants R21 HG007554 and R01 NS094637. ERA and EE were supported by the MINECO and FEDER (BIO2014-52566-R), AGAUR (SGR2014-1121), and the Sandra Ibarra Foundation for Cancer (FSI2013).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The prognostic potential of alternative transcript isoforms across human tumors

  • Trincado Alonso, Juan Luis, 1987-
  • Sebestyén, Endre
  • Pagès Pinós, Amadís
  • Eyras Jiménez, Eduardo
Background: Phenotypic changes during cancer progression are associated with alterations in gene expression, which can be exploited to build molecular signatures for tumor stage identification and prognosis. However, it is not yet known whether the relative abundance of transcript isoforms may be informative for clinical stage and survival. Methods: Using information theory and machine learning methods, we integrated RNA sequencing and clinical data from The Cancer Genome Atlas project to perform the first systematic analysis of the prognostic potential of transcript isoforms in 12 solid tumors to build new signatures for stage and prognosis. This study was also performed in breast tumors according to estrogen receptor (ER) status and melanoma tumors with proliferative and invasive phenotypes. Results: Transcript isoform signatures accurately separate early from late-stage groups and metastatic from non-metastatic tumors, and are predictive of the survival of patients with undetermined lymph node invasion or metastatic status. These signatures show similar, and sometimes better, accuracies compared with known gene expression signatures in retrospective data and are largely independent of gene expression changes. Furthermore, we show frequent transcript isoform changes in breast tumors according to ER status, and in melanoma tumors according to the invasive or proliferative phenotype, and derive accurate predictive models of stage and survival within each patient subgroup. Conclusions: Our analyses reveal new signatures based on transcript isoform abundances that characterize tumor phenotypes and their progression independently of gene expression. Transcript isoform signatures appear especially relevant to determine lymph node invasion and metastasis and may potentially contribute towards current strategies of precision cancer medicine., This work was supported by grants BIO2014-52566-R and Consolider RNAREG (CSD2009-00080) from the MINECO (Spanish Government) and FEDER, by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The role of alternative splicing in cancer

  • Singh, Babita, 1986-
  • Eyras Jiménez, Eduardo
The functional capacity of cells is defined by the transcriptome. Many recent studies have identified variations in the transcriptome of tumors due to alternative splicing changes, as well as mutations in splicing factors and regulatory signals in most tumor types. Some of these alterations have been linked to tumor progression, metastasis, therapy resistance, and other oncogenic processes. Here, we describe the different mechanisms that drive splicing changes in tumors and their impact in cancer. Motivated by the current evidence, we propose a model whereby a subset of the splicing patterns contributes to the definition of specific tumor phenotypes, and may hold potential for the development of novel clinical biomarkers and therapeutic approaches., This work was supported by the MINECO and FEDER (BIO2014–52566-R) and AGAUR (SGR2014–1121).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development

  • Rodor, Julie
  • FitzPatrick, David R.
  • Eyras Jiménez, Eduardo
  • Cáceres, Javier F.
Mutations in the RNA-binding protein, RBM10, result in a human syndromic form of cleft palate, termed TARP syndrome. A role for RBM10 in alternative splicing regulation has been previously demonstrated in human cell lines. To uncover the cellular functions of RBM10 in a cell line that is relevant to the phenotype observed in TARP syndrome, we used iCLIP to identify its endogenous RNA targets in a mouse embryonic mandibular cell line. We observed that RBM10 binds to pre-mRNAs with significant enrichment in intronic regions, in agreement with a role for this protein in pre-mRNA splicing. In addition to protein-coding transcripts, RBM10 also binds to a variety of cellular RNAs, including non-coding RNAs, such as spliceosomal small nuclear RNAs, U2 and U12. RNA-seq was used to investigate changes in gene expression and alternative splicing in RBM10 KO mouse mandibular cells and also in mouse ES cells. We uncovered a role for RBM10 in the regulation of alternative splicing of common transcripts in both cell lines but also identified cell-type specific events. Importantly, those pre-mRNAs that display changes in alternative splicing also contain RBM10 iCLIP tags, suggesting a direct role of RBM10 in these events. Finally, we show that depletion of RBM10 in mouse ES cells leads to proliferation defects and to gross alterations in their differentiation potential. These results demonstrate a role for RBM10 in the regulation of alternative splicing in two cell models of mouse early development and suggests that mutations in RBM10 could lead to splicing changes that affect normal palate development and cause human disease., D.R.F. and J.F.C. were supported by Core funding from the Medical Research Council. J.F.C had also funding from the Wellcome Trust (Grant 095518/Z/11/Z). E.E. was supported by MINECO (Ministerio de Economía y Competitividad) and FEDER (Fondo Europeo de Desarrollo Regional) through grant BIO2014-52566-R, by Sandra Ibarra Foundation for Cancer and by AGAUR (Agència de Gestió d'Ajuts Universitaris i de Recerca) through grant 2014-SGR1121.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The functional impact of alternative splicing in cancer

  • Climente González, Héctor
  • Porta-Pardo, Eduard
  • Godzik, Adam
  • Eyras Jiménez, Eduardo
Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remain mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis revealed that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors and potentially disrupt protein-protein interactions in cancer-related pathways. Moreover, there was a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors may represent independent oncogenic processes that could be relevant to explain the functional transformations in cancer, and some of them could potentially be considered alternative splicing drivers (AS drivers)., H.C.-G. and E.E. were supported by the MINECO and FEDER (BIO2014-52566-R), Consolider RNAREG (CSD2009-00080), AGAUR (SGR2014-1121), the European ITN Network RNP-Net (ID: 289007), and the Sandra Ibarra Foundation for Cancer (FSI2013). E.P.-P. and A.G. were supported by the SBP CC grant (P30 CA030199). All authors thank The Cancer Genome Atlas project for making their data publicly available. The Computational RNA Biology Group is part of the Research Programme on Biomedical Informatics (GRIB), which is a member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 (No. 676559) and of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023 of the PE I+D+I 2013-2016, funded by ISCIII and FEDER
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The RNA-binding profile of Acinus, a peripheral component of the exon junction complex, reveals its role in splicing regulation

  • Rodor, Julie
  • Pan, Qun
  • Blencowe, Benjamin J.
  • Eyras Jiménez, Eduardo
  • Cáceres, Javier F.
Acinus (apoptotic chromatin condensation inducer in the nucleus) is an RNA-binding protein (RBP) originally identified for its role in apoptosis. It was later found to be an auxiliary component of the exon junction complex (EJC), which is deposited at exon junctions as a consequence of pre-mRNA splicing. To uncover the cellular functions of Acinus and investigate its role in splicing, we mapped its endogenous RNA targets using the cross-linking immunoprecipitation protocol (iCLIP). We observed that Acinus binds to pre-mRNAs, associating specifically to a subset of suboptimal introns, but also to spliced mRNAs. We also confirmed the presence of Acinus as a peripheral factor of the EJC. RNA-seq was used to investigate changes in gene expression and alternative splicing following siRNA-mediated depletion of Acinus in HeLa cells. This analysis revealed that Acinus is preferentially required for the inclusion of specific alternative cassette exons and also controls the faithful splicing of a subset of introns. Moreover, a large number of splicing changes can be related to Acinus binding, suggesting a direct role of Acinus in exon and intron definition. In particular, Acinus regulates the splicing of DFFA/ICAD transcript, a major regulator of DNA fragmentation. Globally, the genome-wide identification of RNA targets of Acinus revealed its role in splicing regulation as well as its involvement in other cellular pathways, including cell cycle progression. Altogether, this study uncovers new cellular functions of an RBP transiently associated with the EJC., J.F.C. was supported by Core funding from the Medical Research Council and by the Wellcome Trust (grant 095518/Z/11/Z). B.J.B. was supported by grants from the CIHR (Canadian Institutes of Health Research). B.J.B. holds the Banbury Chair in Medical Research at the University of Toronto. E.E. was supported by MINECO (Ministerio de Economía y Competitividad) and FEDER (Fondo Europeo de Desarrollo Regional) through grant BIO2014-52566-R, by Sandra Ibarra Foundation for Cancer, and by AGAUR (Agència de Gestió d'Ajuts Universitaris i de Recerca) through grant 2014-SGR1121.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions

  • Trincado Alonso, Juan Luis, 1987-
  • Entizne, Juan Carlos
  • Hysenaj, Gerald
  • Singh, Babita, 1986-
  • Skalic, Miha, 1990-
  • Elliott, David, 1947-
  • Eyras Jiménez, Eduardo
Despite the many approaches to study differential splicing from RNA-seq, many challenges remain unsolved, including computing capacity and sequencing depth requirements. Here we present SUPPA2, a new method that addresses these challenges, and enables streamlined analysis across multiple conditions taking into account biological variability. Using experimental and simulated data, we show that SUPPA2 achieves higher accuracy compared to other methods, especially at low sequencing depth and short read length. We use SUPPA2 to identify novel Transformer2-regulated exons, novel microexons induced during differentiation of bipolar neurons, and novel intron retention events during erythroblast differentiation., This work was supported by the MINECO and FEDER with grants BIO2014-52566-R and BIO2017-85364-R, by AGAUR with grants SGR2014-1121 and SGR2017-1020, by BBSRC (BB/P006612/1), and by Breast Cancer Now (2014NovPR355). GH is a BBSRC-funded PhD student.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The discovery potential of RNA processing profiles

  • Pagès Pinós, Amadís
  • Dotu, Ivan
  • Pallarès Albanell, Joan, 1988-
  • Martí Puig, Eulàlia
  • Guigó Serra, Roderic
  • Eyras Jiménez, Eduardo
Small non-coding RNAs (sncRNAs) are highly abundant molecules that regulate essential cellular processes and are classified according to sequence and structure. Here we argue that read profiles from size-selected RNA sequencing capture the post-transcriptional processing specific to each RNA family, thereby providing functional information independently of sequence and structure. We developed SeRPeNT, a new computational method that exploits reproducibility across replicates and uses dynamic time-warping and density-based clustering algorithms to identify, characterize and compare sncRNAs by harnessing the power of read profiles. We applied SeRPeNT to: (i) generate an extended human annotation with 671 new sncRNAs from known classes and 131 from new potential classes, (ii) show pervasive differential processing of sncRNAs between cell compartments and (iii) predict new molecules with miRNA-like behaviour from snoRNA, tRNA and long non-coding RNA precursors, potentially dependent on the miRNA biogenesis pathway. Furthermore, we validated experimentally four predicted novel non-coding RNAs: a miRNA, a snoRNA-derived miRNA, a processed tRNA and a new uncharacterized sncRNA. SeRPeNT facilitates fast and accurate discovery and characterization of sncRNAs at an unprecedented scale. SeRPeNT code is available under the MIT license at https://github.com/comprna/SeRPeNT., MINECO (to E.E., A.P.); FEDER [BIO2014-52566-R to E.E., A.P.]; Consolider RNAREG [CSD2009-00080 to E.E., A.P.]; AGAUR [SGR2014-1121 to E.E., A.P.]; European ITN Network RNP-Net [ID:289007 to E.E., A.P.]; Sandra Ibarra Foundation for Cancer [FSI2013 to E.E., A.P.]; MINECO [BIO2011-26205 to R.G., A.P., SAF2014-60551-R to E.M., J.P.A.]; National Human Genome Research Institute of the National Institutes of Health [U54HG007004 to R.G., A.P.]; MINECO Centro de Excelencia Severo Ochoa 2013-2017 [SEV-2012-0208 to R.G., A.P.]; Research Programme on Biomedical Informatics (GRIB), which is member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 [676559 to E.E., A.P., I.D.]; ELIXIR-Excelerate, European Union Horizon 2020 Spanish National Bioinformatics Institute (INB) [PT13/0001/0023 to E.E., A.P., I.D.]. Funding for open access charge: European ITN Network RNP-Net [ID:289007] and MINECO-FEDER [BIO2014-52566-R].
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

The Functional Impact of Alternative Splicing in Cancer

  • Climente-Gonzalez, Héctor
  • Porta-Pardo, Eduard
  • Godzik, Adam
  • Eyras, Eduardo
Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remain mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis revealed that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors and potentially disrupt protein-protein interactions in cancer-related pathways. Moreover, there was a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors may represent independent oncogenic processes that could be relevant to explain the functional transformations in cancer, and some of them could potentially be considered alternative splicing drivers (AS drivers)., H.C.-G. and E.E. were supported by the MINECO and FEDER (BIO2014-52566-R), Consolider RNAREG (CSD2009-00080), AGAUR (SGR2014-1121), the European ITN Network RNP-Net (ID: 289007), and the Sandra Ibarra Foundation for Cancer (FSI2013). E.P.-P. and A.G. were supported by the SBP CC grant (P30 CA030199). All authors thank The Cancer Genome Atlas project for making their data publicly available. The Computational RNA Biology Group is part of the Research Programme on Biomedical Informatics (GRIB), which is a member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 (No. 676559) and of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023 of the PE I+D+I 2013-2016, funded by ISCIII and FEDER., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The discovery potential of RNA processing profiles

  • Pagès Pinós, Amadís
  • Dotu, Ivan
  • Pallarès Albanell, Joan, 1988-
  • Martí Puig, Eulàlia
  • Guigó Serra, Roderic
  • Eyras Jiménez, Eduardo
Small non-coding RNAs (sncRNAs) are highly abundant molecules that regulate essential cellular processes and are classified according to sequence and structure. Here we argue that read profiles from size-selected RNA sequencing capture the post-transcriptional processing specific to each RNA family, thereby providing functional information independently of sequence and structure. We developed SeRPeNT, a new computational method that exploits reproducibility across replicates and uses dynamic time-warping and density-based clustering algorithms to identify, characterize and compare sncRNAs by harnessing the power of read profiles. We applied SeRPeNT to: (i) generate an extended human annotation with 671 new sncRNAs from known classes and 131 from new potential classes, (ii) show pervasive differential processing of sncRNAs between cell compartments and (iii) predict new molecules with miRNA-like behaviour from snoRNA, tRNA and long non-coding RNA precursors, potentially dependent on the miRNA biogenesis pathway. Furthermore, we validated experimentally four predicted novel non-coding RNAs: a miRNA, a snoRNA-derived miRNA, a processed tRNA and a new uncharacterized sncRNA. SeRPeNT facilitates fast and accurate discovery and characterization of sncRNAs at an unprecedented scale. SeRPeNT code is available under the MIT license at https://github.com/comprna/SeRPeNT., MINECO (to E.E., A.P.); FEDER [BIO2014-52566-R to E.E., A.P.]; Consolider RNAREG [CSD2009-00080 to E.E., A.P.]; AGAUR [SGR2014-1121 to E.E., A.P.]; European ITN Network RNP-Net [ID:289007 to E.E., A.P.]; Sandra Ibarra Foundation for Cancer [FSI2013 to E.E., A.P.]; MINECO [BIO2011-26205 to R.G., A.P., SAF2014-60551-R to E.M., J.P.A.]; National Human Genome Research Institute of the National Institutes of Health [U54HG007004 to R.G., A.P.]; MINECO Centro de Excelencia Severo Ochoa 2013-2017 [SEV-2012-0208 to R.G., A.P.]; Research Programme on Biomedical Informatics (GRIB), which is member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 [676559 to E.E., A.P., I.D.]; ELIXIR-Excelerate, European Union Horizon 2020 Spanish National Bioinformatics Institute (INB) [PT13/0001/0023 to E.E., A.P., I.D.]. Funding for open access charge: European ITN Network RNP-Net [ID:289007] and MINECO-FEDER [BIO2014-52566-R].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SARNAclust: Semi-automatic detection of RNA protein binding motifs from immunoprecipitation data

  • Dotu, Ivan
  • Scott I. Adamson
  • Coleman, Benjamin
  • Fournier, Cyril
  • Ricart Altimiras, Emma
  • Eyras Jiménez, Eduardo
  • Chuang, Jeffrey H.
RNA-protein binding is critical to gene regulation, controlling fundamental processes including splicing, translation, localization and stability, and aberrant RNA-protein interactions are known to play a role in a wide variety of diseases. However, molecular understanding of RNA-protein interactions remains limited; in particular, identification of RNA motifs that bind proteins has long been challenging, especially when such motifs depend on both sequence and structure. Moreover, although RNA binding proteins (RBPs) often contain more than one binding domain, algorithms capable of identifying more than one binding motif simultaneously have not been developed. In this paper we present a novel pipeline to determine binding peaks in crosslinking immunoprecipitation (CLIP) data, to discover multiple possible RNA sequence/structure motifs among them, and to experimentally validate such motifs. At the core is a new semi-automatic algorithm SARNAclust, the first unsupervised method to identify and deconvolve multiple sequence/structure motifs simultaneously. SARNAclust computes similarity between sequence/structure objects using a graph kernel, providing the ability to isolate the impact of specific features through the bulge graph formalism. Application of SARNAclust to synthetic data shows its capability of clustering 5 motifs at once with a V-measure value of over 0.95, while GraphClust achieves only a V-measure of 0.083 and RNAcontext cannot detect any of the motifs. When applied to existing eCLIP sets, SARNAclust finds known motifs for SLBP and HNRNPC and novel motifs for several other RBPs such as AGGF1, AKAP8L and ILF3. We demonstrate an experimental validation protocol, a targeted Bind-n-Seq-like high-throughput sequencing approach that relies on RNA inverse folding for oligo pool design, that can validate the components within the SLBP motif. Finally, we use this protocol to experimentally interrogate the SARNAclust motif predictions for protein ILF3. Our results support a newly identified partially double-stranded UUUUUGAGA motif similar to that known for the splicing factor HNRNPC., JHC was supported by NIH grants R21 HG007554 and R01 NS094637. ERA and EE were supported by the MINECO and FEDER (BIO2014-52566-R), AGAUR (SGR2014-1121), and the Sandra Ibarra Foundation for Cancer (FSI2013).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of alternative splicing in cancer

  • Singh, Babita, 1986-
  • Eyras Jiménez, Eduardo
The functional capacity of cells is defined by the transcriptome. Many recent studies have identified variations in the transcriptome of tumors due to alternative splicing changes, as well as mutations in splicing factors and regulatory signals in most tumor types. Some of these alterations have been linked to tumor progression, metastasis, therapy resistance, and other oncogenic processes. Here, we describe the different mechanisms that drive splicing changes in tumors and their impact in cancer. Motivated by the current evidence, we propose a model whereby a subset of the splicing patterns contributes to the definition of specific tumor phenotypes, and may hold potential for the development of novel clinical biomarkers and therapeutic approaches., This work was supported by the MINECO and FEDER (BIO2014–52566-R) and AGAUR (SGR2014–1121).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Functional Impact of Alternative Splicing in Cancer

  • Climente-Gonzalez, Héctor
  • Porta-Pardo, Eduard
  • Godzik, Adam
  • Eyras, Eduardo
Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remain mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis revealed that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors and potentially disrupt protein-protein interactions in cancer-related pathways. Moreover, there was a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors may represent independent oncogenic processes that could be relevant to explain the functional transformations in cancer, and some of them could potentially be considered alternative splicing drivers (AS drivers)., H.C.-G. and E.E. were supported by the MINECO and FEDER (BIO2014-52566-R), Consolider RNAREG (CSD2009-00080), AGAUR (SGR2014-1121), the European ITN Network RNP-Net (ID: 289007), and the Sandra Ibarra Foundation for Cancer (FSI2013). E.P.-P. and A.G. were supported by the SBP CC grant (P30 CA030199). All authors thank The Cancer Genome Atlas project for making their data publicly available. The Computational RNA Biology Group is part of the Research Programme on Biomedical Informatics (GRIB), which is a member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 (No. 676559) and of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023 of the PE I+D+I 2013-2016, funded by ISCIII and FEDER., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The prognostic potential of alternative transcript isoforms across human tumors

  • Trincado Alonso, Juan Luis, 1987-
  • Sebestyén, Endre
  • Pagès Pinós, Amadís
  • Eyras Jiménez, Eduardo
Background: Phenotypic changes during cancer progression are associated with alterations in gene expression, which can be exploited to build molecular signatures for tumor stage identification and prognosis. However, it is not yet known whether the relative abundance of transcript isoforms may be informative for clinical stage and survival. Methods: Using information theory and machine learning methods, we integrated RNA sequencing and clinical data from The Cancer Genome Atlas project to perform the first systematic analysis of the prognostic potential of transcript isoforms in 12 solid tumors to build new signatures for stage and prognosis. This study was also performed in breast tumors according to estrogen receptor (ER) status and melanoma tumors with proliferative and invasive phenotypes. Results: Transcript isoform signatures accurately separate early from late-stage groups and metastatic from non-metastatic tumors, and are predictive of the survival of patients with undetermined lymph node invasion or metastatic status. These signatures show similar, and sometimes better, accuracies compared with known gene expression signatures in retrospective data and are largely independent of gene expression changes. Furthermore, we show frequent transcript isoform changes in breast tumors according to ER status, and in melanoma tumors according to the invasive or proliferative phenotype, and derive accurate predictive models of stage and survival within each patient subgroup. Conclusions: Our analyses reveal new signatures based on transcript isoform abundances that characterize tumor phenotypes and their progression independently of gene expression. Transcript isoform signatures appear especially relevant to determine lymph node invasion and metastasis and may potentially contribute towards current strategies of precision cancer medicine., This work was supported by grants BIO2014-52566-R and Consolider RNAREG (CSD2009-00080) from the MINECO (Spanish Government) and FEDER, by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The RNA-binding profile of Acinus, a peripheral component of the exon junction complex, reveals its role in splicing regulation

  • Rodor, Julie
  • Pan, Qun
  • Blencowe, Benjamin J.
  • Eyras Jiménez, Eduardo
  • Cáceres, Javier F.
Acinus (apoptotic chromatin condensation inducer in the nucleus) is an RNA-binding protein (RBP) originally identified for its role in apoptosis. It was later found to be an auxiliary component of the exon junction complex (EJC), which is deposited at exon junctions as a consequence of pre-mRNA splicing. To uncover the cellular functions of Acinus and investigate its role in splicing, we mapped its endogenous RNA targets using the cross-linking immunoprecipitation protocol (iCLIP). We observed that Acinus binds to pre-mRNAs, associating specifically to a subset of suboptimal introns, but also to spliced mRNAs. We also confirmed the presence of Acinus as a peripheral factor of the EJC. RNA-seq was used to investigate changes in gene expression and alternative splicing following siRNA-mediated depletion of Acinus in HeLa cells. This analysis revealed that Acinus is preferentially required for the inclusion of specific alternative cassette exons and also controls the faithful splicing of a subset of introns. Moreover, a large number of splicing changes can be related to Acinus binding, suggesting a direct role of Acinus in exon and intron definition. In particular, Acinus regulates the splicing of DFFA/ICAD transcript, a major regulator of DNA fragmentation. Globally, the genome-wide identification of RNA targets of Acinus revealed its role in splicing regulation as well as its involvement in other cellular pathways, including cell cycle progression. Altogether, this study uncovers new cellular functions of an RBP transiently associated with the EJC., J.F.C. was supported by Core funding from the Medical Research Council and by the Wellcome Trust (grant 095518/Z/11/Z). B.J.B. was supported by grants from the CIHR (Canadian Institutes of Health Research). B.J.B. holds the Banbury Chair in Medical Research at the University of Toronto. E.E. was supported by MINECO (Ministerio de Economía y Competitividad) and FEDER (Fondo Europeo de Desarrollo Regional) through grant BIO2014-52566-R, by Sandra Ibarra Foundation for Cancer, and by AGAUR (Agència de Gestió d'Ajuts Universitaris i de Recerca) through grant 2014-SGR1121.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers

  • Pérez-Guijarro, Eva
  • Bellora Pereyra, Nicolás
  • Eyras Jiménez, Eduardo
  • Soengas, María S.
Nuclear 3’-end-polyadenylation is essential for the transport, stability and translation of virtually all eukaryotic mRNAs. Poly(A) tail extension can also occur in the cytoplasm, but the transcripts involved are incompletely understood, particularly in cancer. Here we identify a lineage-specific requirement of the cytoplasmic polyadenylation binding protein 4 (CPEB4) in malignant melanoma. CPEB4 is upregulated early in melanoma progression, as defined by computational and histological analyses. Melanoma cells are distinct from other tumour cell types in their dependency on CPEB4, not only to prevent mitotic aberrations, but to progress through G1/S cell cycle checkpoints. RNA immunoprecipitation, sequencing of bound transcripts and poly(A) length tests link the melanoma-specific functions of CPEB4 to signalling hubs specifically enriched in this disease. Essential in these CPEB4-controlled networks are the melanoma drivers MITF and RAB7A, a feature validated in clinical biopsies. These results provide new mechanistic links between cytoplasmic polyadenylation and lineage specification in melanoma., M.S.S. was funded by Marató TVE and Consolider RNAREG (CSD2009-00080), and SAF2014-56868-R (Spanish Ministry of Economy and Innovation). R.M. was supported by Fundación Botín, by the Banco Santander through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Innovation (BFU2011–30121 and Consolider RNAREG (CSD2009-00080). J.L.R.-P. was funded by grant FIS 2014/1737 from the Spanish Ministry of Health, P.L.O.-R. by FIS 14/1784; and N.B. and E.E. by MINECO and FEDER (BIO2014-52566-R), as well as by Consolider RNAREG (CSD2009-00080), by AGAUR (2014-SGR1121) and by the Sandra Ibarra Foundation for Cancer (FSI2013). C.R.G was funded by Ludwig Institute for Cancer Research. E.P.-G., D.A.-C. and R.M.-H. are recipients of Scientists in Training predoctoral fellowships from the Spanish Ministry of Science and Innovation. P.K and M.C. are funded by a predoctoral fellowship from Fundación La Caixa. E.R.-F. is the recipient of a postdoctoral fellowship from ‘Fundación Científica de la Asociación Española Contra el Cáncer’ and supported by FMM-2013/0075 of Fundacion Mutua Madrileña.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The RNA-binding landscape of RBM10 and its role in alternative splicing regulation in models of mouse early development

  • Rodor, Julie
  • FitzPatrick, David R.
  • Eyras Jiménez, Eduardo
  • Cáceres, Javier F.
Mutations in the RNA-binding protein, RBM10, result in a human syndromic form of cleft palate, termed TARP syndrome. A role for RBM10 in alternative splicing regulation has been previously demonstrated in human cell lines. To uncover the cellular functions of RBM10 in a cell line that is relevant to the phenotype observed in TARP syndrome, we used iCLIP to identify its endogenous RNA targets in a mouse embryonic mandibular cell line. We observed that RBM10 binds to pre-mRNAs with significant enrichment in intronic regions, in agreement with a role for this protein in pre-mRNA splicing. In addition to protein-coding transcripts, RBM10 also binds to a variety of cellular RNAs, including non-coding RNAs, such as spliceosomal small nuclear RNAs, U2 and U12. RNA-seq was used to investigate changes in gene expression and alternative splicing in RBM10 KO mouse mandibular cells and also in mouse ES cells. We uncovered a role for RBM10 in the regulation of alternative splicing of common transcripts in both cell lines but also identified cell-type specific events. Importantly, those pre-mRNAs that display changes in alternative splicing also contain RBM10 iCLIP tags, suggesting a direct role of RBM10 in these events. Finally, we show that depletion of RBM10 in mouse ES cells leads to proliferation defects and to gross alterations in their differentiation potential. These results demonstrate a role for RBM10 in the regulation of alternative splicing in two cell models of mouse early development and suggests that mutations in RBM10 could lead to splicing changes that affect normal palate development and cause human disease., D.R.F. and J.F.C. were supported by Core funding from the Medical Research Council. J.F.C had also funding from the Wellcome Trust (Grant 095518/Z/11/Z). E.E. was supported by MINECO (Ministerio de Economía y Competitividad) and FEDER (Fondo Europeo de Desarrollo Regional) through grant BIO2014-52566-R, by Sandra Ibarra Foundation for Cancer and by AGAUR (Agència de Gestió d'Ajuts Universitaris i de Recerca) through grant 2014-SGR1121.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions

  • Trincado Alonso, Juan Luis, 1987-
  • Entizne, Juan Carlos
  • Hysenaj, Gerald
  • Singh, Babita, 1986-
  • Skalic, Miha, 1990-
  • Elliott, David, 1947-
  • Eyras Jiménez, Eduardo
Despite the many approaches to study differential splicing from RNA-seq, many challenges remain unsolved, including computing capacity and sequencing depth requirements. Here we present SUPPA2, a new method that addresses these challenges, and enables streamlined analysis across multiple conditions taking into account biological variability. Using experimental and simulated data, we show that SUPPA2 achieves higher accuracy compared to other methods, especially at low sequencing depth and short read length. We use SUPPA2 to identify novel Transformer2-regulated exons, novel microexons induced during differentiation of bipolar neurons, and novel intron retention events during erythroblast differentiation., This work was supported by the MINECO and FEDER with grants BIO2014-52566-R and BIO2017-85364-R, by AGAUR with grants SGR2014-1121 and SGR2017-1020, by BBSRC (BB/P006612/1), and by Breast Cancer Now (2014NovPR355). GH is a BBSRC-funded PhD student.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The functional impact of alternative splicing in cancer

  • Climente González, Héctor
  • Porta-Pardo, Eduard
  • Godzik, Adam
  • Eyras Jiménez, Eduardo
Alternative splicing changes are frequently observed in cancer and are starting to be recognized as important signatures for tumor progression and therapy. However, their functional impact and relevance to tumorigenesis remain mostly unknown. We carried out a systematic analysis to characterize the potential functional consequences of alternative splicing changes in thousands of tumor samples. This analysis revealed that a subset of alternative splicing changes affect protein domain families that are frequently mutated in tumors and potentially disrupt protein-protein interactions in cancer-related pathways. Moreover, there was a negative correlation between the number of these alternative splicing changes in a sample and the number of somatic mutations in drivers. We propose that a subset of the alternative splicing changes observed in tumors may represent independent oncogenic processes that could be relevant to explain the functional transformations in cancer, and some of them could potentially be considered alternative splicing drivers (AS drivers)., H.C.-G. and E.E. were supported by the MINECO and FEDER (BIO2014-52566-R), Consolider RNAREG (CSD2009-00080), AGAUR (SGR2014-1121), the European ITN Network RNP-Net (ID: 289007), and the Sandra Ibarra Foundation for Cancer (FSI2013). E.P.-P. and A.G. were supported by the SBP CC grant (P30 CA030199). All authors thank The Cancer Genome Atlas project for making their data publicly available. The Computational RNA Biology Group is part of the Research Programme on Biomedical Informatics (GRIB), which is a member of ELIXIR-Excelerate of the European Union Horizon 2020 Programme 2014-2020 (No. 676559) and of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023 of the PE I+D+I 2013-2016, funded by ISCIII and FEDER